Stoke Therapeutics Inc [STOK] stock prices are up 12.08% to $34.15 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The STOK shares have gain 10.30% over the last week, with a monthly amount glided 52.66%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Stoke Therapeutics Inc [NASDAQ: STOK] stock has seen the most recent analyst activity on July 18, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $30. Previously, Chardan Capital Markets started tracking the stock with Buy rating on December 20, 2024, and set its price target to $24. TD Cowen upgraded its rating to an Outperform. TD Cowen downgraded its rating to Market Perform for this stock on July 25, 2023. In a note dated May 01, 2023, BofA Securities upgraded a Neutral rating on this stock and boosted its target price from $9 to $12.
The stock price of Stoke Therapeutics Inc [STOK] has been fluctuating between $5.35 and $38.69 over the past year. Currently, Wall Street analysts expect the stock to reach $30.33 within the next 12 months. Stoke Therapeutics Inc [NASDAQ: STOK] shares were valued at $34.15 at the most recent close of the market. An investor can expect a potential drop of -11.19% based on the average STOK price forecast.
Analyzing the STOK fundamentals
The Stoke Therapeutics Inc [NASDAQ:STOK] reported sales of 205.63M for trailing twelve months, representing a surge of 117.25%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at 0.2%, and Net Profit Margin reading is 0.2%. To continue investigating profitability, this company’s Return on Assets is posted at 0.11, Equity is 0.13 and Total Capital is 0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 31.10 points at the first support level, and at 28.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 36.27, and for the 2nd resistance point, it is at 38.39.
Ratios To Look Out For
It’s worth pointing out that Stoke Therapeutics Inc [NASDAQ:STOK]’s Current Ratio is 6.53. Also, the Quick Ratio is 6.53, while the Cash Ratio stands at 2.0. Considering the valuation of this stock, the price to sales ratio is 9.49, the price to book ratio is 6.11 and price to earnings (TTM) ratio is 51.75.
Transactions by insiders
Recent insider trading involved Allan Jonathan, GENERAL COUNSEL & CORP SEC, that happened on Dec 08 ’25 when 3978.0 shares were sold. Director, Kaye Edward M. MD completed a deal on Dec 08 ’25 to sell 13430.0 shares. Meanwhile, Director EDWARD M KAYE bought 13430.0 shares on Dec 08 ’25.
